1 CIPROFLOXACIN FOR PROPHYLAXIS OF CLINICAL DISEASE DUE TO INHALED B. anthracis Anti-Infectives Advisory Committee Meeting July 28, 2000 Andrea Meyerhoff.

Slides:



Advertisements
Similar presentations
FHM TRAINING TOOLS This training presentation is part of FHM’s commitment to creating and keeping safe workplaces. Be sure to check out all the training.
Advertisements

Responding to the Threat of Bioterrorism: A Status Report on Vaccine Research in the United States Good Morning. Over the next 1 ½ hours of so I’ll be.
Fundamentals New Anthrax Countermeasure* Vi Pham**, Zachary Taylor** and Miguel Bagajewicz University of Oklahoma - Chemical Engineering (*) This work.
Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
BW Agents: Anthrax J.A. Sliman, MD, MPH LCDR MC(FS) USN Preventive Medicine Resident Johns Hopkins Bloomberg School of Public Health.
Oncologic Drugs Advisory Committee
Anthrax. References What You Need to Know Frequently Asked Questions
BIOLOGICAL AGENTS  CDC has prioritized them in Lists A - C  A List:  Easily transmitted/disseminated  High mortality rate  Potential for public panic.
Bacterial agents of bioterroism. Laboratory network for biological terrorism.
Bacillus  ~ 60 species; Gram-positive or Gram-variable bacilli Large (0.5 x 1.2 to 2.5 x 10 um) Most are saprophytic contaminants or normal flora Bacillus.
ANTHRAX By: Justin Tursellino. Anthrax is a…. Anthrax is an infection caused by a bacterium, Bacillus anthracis. The infection can take three forms depending.
American Conference on Pharmacometics –San Diego, CA; April Population PK modeling incorporating enzyme induction mechanism to guide the design.
Overview of Auxiliary Distribution Plan NYC Department of Health and Mental Hygiene November 15, 2011.
Streptococcus pneumoniae Chapter 23. Streptococcus pneumoniae S. pneumoniae was isolated independently by Pasteur and Steinberg more than 100 years ago.
1 CIPROFLOXACIN FOR PROPHYLAXIS OF CLINICAL DISEASE DUE TO INHALED B. anthracis.
Anthrax Sung Chul Hwang, M.D. Dept. of Pulmonary and Critical Care Medicine Ajou University School of Medicine.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Venkata Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Anthrax Vaccine Protocol Jairam Lingappa, MD Meningitis & Special Pathogens Branch, Division of Bacterial and Mycotic Diseases, NCID, CDC Speaker 2 of.
CBER Perspective VRBPAC Meeting, November 16, 2010.
Stages of drug development
Measles Antibody Levels in U.S. Immune Globulin Products
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
July 2015 PRABHAVATHI FERNANDES, PhD Founder, President and CEO How the PATH Act Can Rejuvenate Antibiotic R & D.
1 FDA Review of NDA Valganciclovir for the Treatment of CMV Retinitis in AIDS Joseph Toerner, MD Medical Officer DAVDP.
Pandemic Influenza; A Harbinger of Things to Come Michael T Osterholm PhD, MPH Director, Center for Infectious Disease Research and Policy Associate Director,
Anthrax (Bacillus anthracis) As a Bioterrorism Agent.
39187n n n
1 Data from Studies in One Indication Supporting Studies in a Different Indication March 5, 2003 Anti Infective Drugs Advisory Committee Meeting Edward.
1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.
Vibrio cholerae Asiatic or Epidemic Cholera. Readings Question #1 Describe the Vibrio cholerae bacterium. Where is it found?
Counter-terrorism at FDA Andrea Meyerhoff MD Director, Office of Counter-terrorism US Food and Drug Administration.
CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.
Anthrax March 23 rd, Bacterial pathogens in soil Many bacteria are natural residents of the soil Some are pathogens Some are zoonoses For the most.
Anthrax and Anthrax Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and.
Who is Bacillus? Gram + spore former Good things about Bacillus?
Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.
Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Rationale for Additional Post-Exposure Prophylaxis Options Bradley A. Perkins, M.D. Meningitis & Special Pathogens Branch, Division of Bacterial and Mycotic.
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
Pathway to Licensure for Protective Antigen-based Anthrax Vaccines for a Post-exposure Prophylaxis Indication Using the Animal Rule.
ANTHRAX D. Goldberg, MD Ped ID Service WRAMC. Anthrax Etiology-Bacillus anthracis toxin producing gram positive encapsulated spore forming non motile.
Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
Smallpox vaccine in combination with ST-246 Robert Jordan, Ph.D. SIGA Technologies, Inc FDA – Public HearingMay 17, 2007.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Bacillus D.
Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.
Bacillus SaprophyticB.cereusB.subtilisB.megateriumB.CirculansPathogenicB.anthracis.
Scientific Basis for Review of Varicella Zoster Immune Globulin Products Blood Products Advisory Committee July 21, 2005 Dorothy Scott, M.D. OBRR/CBER.
RAPAMUNE ® TM I-1 RAPAMUNE ® WYETH-AYERST RESEARCH January 24, 2002 Subcommittee of the Antiviral Drugs Advisory Committee on Immunosuppressive Drugs January.
Options for Preventing Anthrax After Exposure: Summary for Clinicians & Public Health Officials Julie Louise Gerberding, MD, MPH Acting Deputy Director.
Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.
Mumps and Mumps Vaccine
Anthrax Human anthrax is typically an ulcerative sore on an exposed part of the body. Constitutional symptoms are minimal, and the ulcer usually resolves.
The aminoglycoside antibiotics
Simone M. Shurland, Ph.D., Division of Anti-Infective Products
Anthrax Zoonotic disease caused by Bacillus anthracis
Pharmacokinetics and pharmacodynamics of fluoroquinolones
Mustansiriyah University College of science Biology Dept
P. Moreillon, J.M. Entenza  Clinical Microbiology and Infection 
M.R. Jacobs  Clinical Microbiology and Infection 
Volume 151, Issue 4, Pages (April 2017)
New Models of Care in Idiopathic Pulmonary Fibrosis
BW Agents: Plague J.A. Sliman, MD, MPH LCDR MC(FS) USN
Presentation transcript:

1 CIPROFLOXACIN FOR PROPHYLAXIS OF CLINICAL DISEASE DUE TO INHALED B. anthracis Anti-Infectives Advisory Committee Meeting July 28, 2000 Andrea Meyerhoff MD MSc DTMH Division of Special Pathogens, US FDA

2 Overview Inhalational anthrax Drugs for anthrax Microbiology of Bacillus anthracis Cipro pharmacology-animal and human Studies of post exposure prophylaxis

3 Inhalational anthrax First described British textile mills 19th c Woolsorters’ or ragpickers’ disease Largely an industrial / occupational infection Rare; US ~20 cases since 1900 Hemorrhagic mediastinitis, with involvement of RES, CNS, and development of sepsis syndrome

4 Inhalational anthrax Clinical entity resulting from intentional use of aerosolized spores B. anthracis Mortality % clinically recognizable disease, even with appropriate therapy Penicillins and/or tetracyclines historically drugs of choice Reports of engineered B. anthracis strains PCN-R, TCN-R

5 Drugs for anthrax: regulatory status No drug is approved for prophylaxis of inhalational anthrax PCNs, TCNs with indications for treatment of clinical disease due to B. anthracis Programs for large scale use in civilian or military personnel, in contrast with practice of medicine, require an approved NDA indication or IND

6 Cipro First formulation (oral) approved US 1987 Approved indications (17) include –lower respiratory tract infections –complicated intraabdominal infections –bone and joint infections –typhoid fever Used by >100 million patients in US

7 Cipro oral Approved doses mg q 12 hour Proposed regimen anthrax prophylaxis: –Adult 500 mg q 12 hour –Pediatric mg/kg q 12 hour –Duration 60 days

8 B. anthracis: Microbiology Spore forming Germinates into vegetative state under certain environmental conditions Vegetative state –encapsulated, toxin-producing: PA, EF, LF –generally PCN, TCN susceptible, 3% PCN-R –bioengineered strains with PCN-R, TCN-R

9 B. anthracis: Microbiology

10 Cipro pharmacology: overview Peak and trough serum concentrations –Macaque monkey –Human –Comparison macaque and human

11 Ciprofloxacin Peak Concentrations - Monkeys (Kelly et al 1992)

12 Ciprofloxacin Trough Concentrations - Monkeys (Kelly et al 1992)

13 Ciprofloxacin Oral Steady State Pharmacokinetics

14 Ciprofloxacin Peak Concentrations - All

15 Ciprofloxacin Trough Concentrations - All

16 Comparison of drug levels with MIC 90 B. anthracis Fluoroquinolones: killing is concentration dependent rather than time dependent Cmax/MIC > 10 desirable range Cipro: B. anthracis –Cipro peak macaque ~33x MIC 90 –Cipro peak human ~50x MIC 90

17 Inhalational anthrax: early theories of pathogenesis Theory #1: Persistent spores –germination pulmonary macrophage (MØ) –toxin production/ early pathology mediastinal lymph nodes Theory #2: Acute bacterial infection –erosion bronchial mucosa –rapid germination pulmonary parenchyma –early pathology pneumonia

18 Early studies inhalational anthrax: post-exposure drug administration Post exposure PCN (Henderson et al 1956) –PCN 24 h post exp macaques for 5, 10, 20 days with controls –survival curves same slope as controls –only delay death

19 Survival curves (Henderson et al 1956)

20 Spore clearance (Henderson et al 1956)

21 Early studies inhalational anthrax: spore clearance from lung (Ross 1957) Guinea pig: # spores reaching regional LN <<< # deposited pulmonary epithelium Differential staining: distinction of stages of spore development and vegetative state Different modes of spore exit from lung –transported to regional LN via pulmonary MØ –phagocytosed spores passed into bronchioles –?spores lysed and destroyed in phagocytic cell

22 Inhalational anthrax: post-exposure drug administration (Friedlander et al 1993) 6 groups/10 animals each –30 days antimicrobial: 1) ciprofloxacin, 2) doxycycline, 3) penicillin, 4) doxy + vaccine –5) vaccine, 6) control Survival following aerosol challenge days Mortality rates –at 90 days (evaluable population) –up to 130 days (ITT population)

23 Challenge (from Friedlander et al 1993) Survival TOC End of treatment

24 Challenge (from Friedlander et al 1993) Survival TOC End of treatment

25 Intent-to-treat Analysis: Including all cause of death up to re-challenge

26 Evaluable Population Analysis: Cause of death proven to be due to Anthax (TOC=90)

27 Prevention of inhalational anthrax: duration of drug administration 5, 10, 20 days too short 30 days look better Of the ciprofloxacin cohort, one anthrax death at 36 days Spore load decreases over time Is there a minimum?

28 Prevention of inhalational anthrax: human epidemiology Sverdlovsk 1979 published account: longest incubation fatal case 43 days –Patient #42 Industrial exposure –nonimmunized mill workers inhale anthrax-contaminated particles < 5µ/ shift –clinical disease rare –likelihood of development of anthrax independent of duration of employment

29 Summary: Inhalational anthrax Rare, rapidly progressive disease with very high mortality Little opportunity to improve outcome with treatment once clinical disease recognized Identified as a clinical manifestation of a biological agent of highest potential concern

30 Summary: Inhalational anthrax Currently no drug approved for prophylaxis Cannot be studied in humans Non-human primate model demonstrates similar pathology and mortality as humans

31 Summary: Ciprofloxacin Post-exposure administration in primate model shown to significantly improve survival compared with placebo Comparable blood levels achieved with –dose used* for successful prophylaxis in primate model of inhalational anthrax –500 mg po q 12 hours in adults –15 mg/kg po q 12 hours in children Blood levels achieved experimental animals and humans ~30-50x MIC 90 B. anthracis *250 mg followed by 125 mg q 12 hr

32 Summary: Ciprofloxacin Broad array of indications with substantial clinical experience Well-characterized safety database

33 Summary: Prophylaxis of inhalational anthrax Prophylaxis an effort to reduce risk Ciprofloxacin survival better than placebo following 30-day regimen Epidemiologic data suggest duration of drug administration at least 45 days Duration of proposed regimen is 60 days

34 Question #1 for committee Do the data presented support the safety and efficacy of ciprofloxacin for post-exposure prophylaxis of inhalational anthrax?

35 Question #2 for committee If yes, is 60 days an appropriate duration of ciprofloxacin administration for this indication?

36 Acknowledgements Peter Dionne, M.S., Microbiology Reviewer Shukal Bala, Ph.D., Microbiology Reviewer Stephen Hundley, Ph.D., DABT, Pharmacology- Toxicology Reviewer Joette Meyer, Pharm.D., Clinical Pharmacology and Biopharmaceutics Reviewer Karen Higgins Sc.D., Biometrics Team Leader Valerie Jensen R.Ph., Regulatory Project Manager Leo Chan R.Ph., Regulatory Project Manager